ArticleBMC infectious diseases2025
Bloodstream infections: trends in etiology and antimicrobial resistance in 10 years in Eastern Nepal.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Evaluating long-read metagenomics for bloodstream infection diagnostics: a pilot study from a Thai Tertiary Hospital.Scientific reports · 2026Article
- Article
- Distribution and Antimicrobial Resistance Trends of Bloodstream Bacterial Isolates: A 10-year Single-Center Study in China.Infection and drug resistance · 2026Article
- Distribution and antimicrobial resistance profiles of common blood culture isolates in a maternal and child health specialty hospital, Shenzhen (January 2021-October 2025), China.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBloodstream infections (BSIs) are defined as the presence of viable infectious microorganisms in the bloodstream causing clinical illness. Early diagnosis and prompt administration of antimicrobial therapy in patients with BSIs have been shown to reduce both mortality and morbidity. Local and regional antimicrobial resistance (AMR) surveillance contributes to national efforts, which in turn support global strategies to combat AMR. Therefore, this study was conducted to determine the profile and antimicrobial susceptibility pattern of organisms associated with of BSIs, with the aim of guiding antimicrobial policy. MATERIALS AND
methodsThis was a hospital-based retrospective study. Laboratory records of all blood samples submitted for culture and sensitivity testing to the Department of Microbiology, B. P. Koirala Institute of Health Sciences (BPKIHS) over a 10-year period (January 2012 to December 2021) were analyzed. All the blood samples were processed using conventional culture methods. Bacterial pathogens were identified, and their antimicrobial susceptibility was determined using standard microbiological procedures. Patient's demographic data, organism profiles and antimicrobial susceptibility patterns were analyzed using Microsoft excel.
resultsA total of 79,241 samples were received during the study period. Bacterial growth was observed in 9590 samples with culture positivity of 12.1%. Staphylococcus aureus (44%, n = 4,210) was the most common organism, followed by Acinetobacter baumannii (18%, n = 1,762), Pseudomonas aeruginosa (9%, n = 820), Klebsiella pneumoniae (8%, n = 752) and Enterococcus spp (8%, n = 741). All resistant phenotypes increased over the years, extended-spectrum beta-lactamase (ESBL) producers rising from 11 to 74%, multidrug-resistant (MDR) organisms from 20 to 43%, and extensively drug-resistant (XDR) organisms from 2 to 31%. Among WHO critical priority pathogens, there was a significant rise in third-generation cephalosporin-resistant Enterobacterales (61-81%), carbapenem-resistant Enterobacterales (0-65%) and carbapenem-resistant A. baumannii (15-45%). Similarly, high-priority pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) increased from 16 to 44%, vancomycin-resistant Enterococcus faecium (VRE) from 2 to 17%, and carbapenem-resistant Pseudomonas aeruginosa from 4 to 66%.
conclusionThe rising prevalence of MDR and XDR organisms underscores the growing challenge of managing BSIs effectively, especially in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.